Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and The ECCO guidelines recommended HCV treatment but warn about the risk of IBD reactivation. We aimed to evaluate 1) the effectiveness and safety of direct-acting antivirals (DAAs) in IBD; 2) the interaction of DAAs with IBD drugs Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximatelymillion chronically infected individuals worldwide. management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and European Association for the Study of the Liver; List of panel members (alphabetical order), Berzigotti A, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M, , These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other The modules are based on the EASL Recommendations on Treatment of Hepatitis C on-demand inar and case-based learning quizzes related to the two published PDFs Recommendations for Testing, Managing, and Treating Hepatitis C HCVmillion individuals chronically infected with hepatitis C virus (HCV) worldwide,1,2 many of whom were unaware of their infectionHCV infection remains one of the main causes of chronic liver disease worldwide.1,4 The long-term natural his-tory of HCV infection is highly variable: the hepatic injury can These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in and onwards The EASL Recommendations on Treatment of Hepatitis C describes the current optimal management of patients with acute and chronic HCV infections Hepatitis C virus (HCV) management in Inflammatory Bowel Disease (IBD) is uncertain.
Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and The ECCO guidelines recommended HCV treatment but warn about the risk of IBD reactivation. We aimed to evaluate 1) the effectiveness and safety of direct-acting antivirals (DAAs) in IBD; 2) the interaction of DAAs with IBD drugs Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximatelymillion chronically infected individuals worldwide. management of patients with acute and chronic HCV infections. These recommendations apply to therapies that have been approved by the European Medicines Agency and European Association for the Study of the Liver; List of panel members (alphabetical order), Berzigotti A, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M, , These EASL Recommendations on Treatment of Hepatitis C are intended to assist physicians and other healthcare providers, as well as patients and other The modules are based on the EASL Recommendations on Treatment of Hepatitis C on-demand inar and case-based learning quizzes related to the two published PDFs Recommendations for Testing, Managing, and Treating Hepatitis C HCVmillion individuals chronically infected with hepatitis C virus (HCV) worldwide,1,2 many of whom were unaware of their infectionHCV infection remains one of the main causes of chronic liver disease worldwide.1,4 The long-term natural his-tory of HCV infection is highly variable: the hepatic injury can These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in and onwards The EASL Recommendations on Treatment of Hepatitis C describes the current optimal management of patients with acute and chronic HCV infections Hepatitis C virus (HCV) management in Inflammatory Bowel Disease (IBD) is uncertain.
Français
English
Deutsch
Español
Italiano
Português